Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Shares Outstanding (2023 - 2025)

Metagenomi (MGX) has disclosed Shares Outstanding for 3 consecutive years, with $500.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1236.24% to $500.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $500.0 million, a 1236.24% increase, with the full-year FY2025 number at $500.0 million, up 1236.24% from a year prior.
  • Shares Outstanding was $500.0 million for Q4 2025 at Metagenomi, up from $37.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $500.0 million in Q4 2025 to a low of $3.4 million in Q1 2023.
  • A 3-year average of $64.7 million and a median of $37.4 million in 2024 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 1236.24% in 2025; the steepest drop was 0.23% in 2025.
  • Metagenomi's Shares Outstanding stood at $3.4 million in 2023, then soared by 999.06% to $37.4 million in 2024, then soared by 1236.24% to $500.0 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Shares Outstanding are $500.0 million (Q4 2025), $37.5 million (Q3 2025), and $37.5 million (Q2 2025).